Eisai reports upbeat results from PhIII epilepsy study

Two years after dumping its research program for perampanel as a possible new therapy for Parkinson's, Eisai says that it has reaped positive Phase III data for the drug in epilepsy. Researchers say that E2007 reduced median seizure frequency while increasing the percentage of patients who experienced a big drop in seizure frequency.

Investigators said that they tracked a statistically significant response for patients taking both the 4 mg and 8 mg doses compared to placebo. Two more Phase III studies are also underway.

The global study--Study 306--was conducted primarily in Europe and Asia with 706 patients from 25 countries. Patients were randomized to placebo or one of three perampanel doses: 2 mg, 4 mg or 8 mg.

- check out the Eisai release

Suggested Articles

Yale researchers discovered that AstraZeneca’s anti-VEGF cancer drug cediranib may boost the effectiveness of PARP inhibitors.

AbbVie became yet another biopharma learning that aggressive brain cancer glioblastoma is one of the toughest cancers out there.

With the Shire deal done, Takeda is looking to lighten the load a little from its central R&D base. To that end, it has launched a new biotech, Phathom.